Objective
to compare the clinical outcome of TAVR with surgical replacement in low-risk patients
Study
multicentre, randomised trial (1:1), non inferiority margin 6%
Population
patients with aortic valve-stenosis with STS-PROM risk score less than 4.0%
Endpoints
composite all-cause death, stroke or rehospitalisation at 1 year
Conclusion
the 1-year rate of adverse events in patients with severe aortic stenosis at low risk was significantly lower with TAVR as compared to surgery
Mack et al. N Engl J Med. 2019;380:1695-705
